• HOME PAGE
  • ABOUT US
  • OUR TEAM
    • Doctors
    • Nurses
    • Laboratory Technicians
    • Public Relations
    • Support Staff
  • OUR SERVICES
    • Cancer Diagnosis and Treatment
    • Laboratory Services
    • Nursing Services
  • ARTICLES
    • New Developments in Cancer Treatment
    • New Developments in Lung Cancer Treatment
    • New Developments in Early-Stage Breast Cancer Treatment
    • New Developments in the Treatment of Metastatic Breast Cancer
    • New Developments in Colon Cancer Treatment
    • New Developments in Pancreatic Cancer Treatment
    • New Developments in Prostate Cancer Treatment
  • TANSAN IN THE PRESS
  • EVENTS & DEVELOPMENTS
  • VIDEOS
  • CONTACT
+90 212 225 27 56
  • Home
  • New Developments in Pancreatic Cancer Treatment

New Developments in Pancreatic Cancer Treatment

New Developments in Pancreatic Cancer Treatment

After a pancreatic cancer diagnosis, patients often ask whether a new treatment might be available to them. Recent years have brought important advances, particularly in medicines directed at the tumour’s molecular features. This article focuses on pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Planning care brings together the stage, whether surgery is possible, the patient’s general health and their priorities. [1] Surgery remains central to operable disease, with chemotherapy considered before or afterwards. For advanced disease, treatments such as FOLFIRINOX and gemcitabine with nab-paclitaxel are joined by NALIRIFOX, which contains liposomal irinotecan, as an option for suitable patients. Choosing a multi-drug regimen takes account of everyday functioning and the ability to tolerate side effects. [1,2] KRAS is at the centre of many newer developments. The gene belongs to the RAS signalling system that helps control cell growth and is altered in most pancreatic adenocarcinomas. But KRAS is not a single target: changes include G12D, G12V, G12R and the less common G12C. Knowing that a tumour has a KRAS mutation may therefore be insufficient; the exact change and the medicine’s target both matter. [3,5] An important development in 2026 was oral daraxonrasib. Rather than targeting KRAS G12C alone, it acts more broadly on active RAS proteins. It received US approval for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment or are unsuitable for multiagent systemic therapy. In RASolute 302, it extended survival compared with the chemotherapy treatments studied in previously treated patients. This does not mean that it cures the disease or is suitable for everyone. [3,4] Medicines directed at particular KRAS changes are also being developed. Zoldonrasib, which targets KRAS G12D, is being studied with daraxonrasib as an initial treatment for metastatic disease in the phase III RASolute 309 trial. The aim is to suppress growth signalling through complementary approaches and reduce resistance. This combination remains investigational and should not be presented as an approved routine first-line treatment. [5] Molecular testing can identify options beyond KRAS. For metastatic disease with inherited BRCA1/2 changes, maintenance olaparib may be considered when cancer has not progressed during at least 16 weeks of first-line platinum chemotherapy. Personalised RNA vaccines are also being studied after surgery. Early findings are interesting, but stronger evidence is needed before they can become routine care. [6,7] The effect on everyday life deserves as much discussion as the expected benefit. Pain relief, nutrition and pancreatic enzyme support when needed are important parts of care. Availability in Türkiye and suitable clinical trials should be assessed for the individual patient, leading to a clear and realistic treatment plan. Sources [1] NCI · Pancreatic cancer | [2] NALIRIFOX · FDA | [3] Daraxonrasib · FDA 2026 | [4] RASolute 302 · NEJM | [5] RASolute 309 · NCI | [6] Olaparib · FDA | [7] RNA vaccine · Nature

Surgery retains its primary role in surgically treatable disease; chemotherapy can be included in the plan before or after surgery. In advanced stages, in addition to treatments such as FOLFIRINOX and gemcitabine and nab-paclitaxel, NALIRIFOX containing liposomal irinotecan is also an option for suitable patients. The choice of these multi-drug treatments is made taking into account the person's daily functions and ability to tolerate side effects. [1,2]

At the heart of the new developments is KRAS. This gene is part of the RAS signaling system that directs cell growth; it is altered in the vast majority of pancreatic adenocarcinomas. However, KRAS is not a single target: there are different alterations such as G12D, G12V, G12R and less frequently G12C. Therefore, simply saying "there is a KRAS mutation" may not be enough; the type of alteration and which target the drug is effective against are important. [3,5]

One of the significant developments of 2026 was the oral daraxonrasib. This drug, which targets more broadly active RAS proteins than just KRAS G12C, received approval in the US for adults with metastatic pancreatic adenocarcinoma who have previously received at least one systemic therapy or are unsuitable for multi-drug systemic therapy. In the RASolute 302 study, it extended survival compared to chemotherapy in previously treated patients. These results do not mean that the disease is completely cured or that the drug is suitable for everyone. [3,4]

Drugs targeting specific KRAS alterations are also being developed. The use of zoldonrasibin in combination with daraxonrasible, which targets KRAS G12D, is being investigated in the phase III study RASolute 309 as the first-line treatment for metastatic disease. The aim is to suppress the tumor's growth signal at different points and reduce treatment resistance. This combination is still under investigation; it should not be offered as a routine, approved first-line treatment. [5]

The contribution of molecular studies is not limited to KRAS. In metastatic disease with hereditary BRCA1/2 alterations, olaparib maintenance therapy can be considered if disease progression has not occurred for at least 16 weeks of first-line platinum chemotherapy. Personalized RNA vaccines are also being investigated postoperatively; although early results are interesting, stronger evidence is needed for them to be considered routine treatments. [6,7]

When evaluating these developments, the impact of treatment on daily life should be discussed as much as its benefits. Pain control, nutrition, and, if necessary, pancreatic enzyme supplementation are important components of care. Access to medications in Türkiye and relevant clinical trials should be evaluated according to the patient's condition to create a clear and realistic treatment plan.

Sources  [1] NCI · Pancreatic cancer  |  [2] NALIRIFOX · FDA  |  [3] Daraxonrasib · FDA 2026  |  [4] RASolute 302 · NEJM  |  [5] RASolute 309 · NCI  |  [6] Olaparib · FDA  |  [7] RNA vaccine · Nature

Call

Latest News & Announcements

  • Tansan Oncology Celebrates its 30th Anniversary with Pride.

    As Tansan Oncology, we are a passenger in the field of healthcare...
  • Following the Path of Scientific Progress: Participation of Our Clinical Team in the Turkish Medical Oncology Congress 2026

    Closely following the latest developments in the field of oncology...
  • We need to stop fighting death.

    Click to go to the link. He turned his pocket...
  • Müjdat Gezen wrote: Süalp Tansan | Cumhuriyet

    Click here to go to the link. Kandemir (Kond...
  • ‘'Vitamin D plays a vital role in preventing cancer!'’

    Click here to go to the link. Dr. Sualp Tansa...
  • LAW ON THE PROTECTION OF PERSONAL DATA (LPPD) INFORMATION TEXT
  • PERSONAL DATA STORAGE AND DESTRUCTION POLICY
  • POLICY ON THE PROTECTION AND PROCESSING OF SPECIAL CATEGORY PERSONAL DATA
  • DECLARATION OF EXPLICIT CONSENT UNDER THE PERSONAL DATA PROTECTION LAW (KVKK)
  • SATISFACTION SURVEY

Tansan Oncology © 03.07.2026 All rights reserved.
These articles are written for patient information purposes.

TOP
EN
TR
By continuing to use our website, our privacy policy By doing so, you agree to the use of cookies.